O	0	8	Caffeine	Caffeine	NN	B-NP
O	9	17	inhibits	inhibit	VBZ	B-VP
O	18	27	adenosine	adenosine	NN	B-NP
O	27	28	-	-	HYPH	B-NP
O	28	35	induced	induce	VBN	I-NP
O	36	48	accumulation	accumulation	NN	I-NP
O	49	51	of	of	IN	B-PP
O	52	59	hypoxia	hypoxia	NN	B-NP
O	59	60	-	-	HYPH	B-NP
O	60	69	inducible	inducible	JJ	I-NP
O	70	76	factor	factor	NN	I-NP
O	76	77	-	-	HYPH	O
O	77	83	1alpha	1alpha	NN	B-NP
O	83	84	,	,	,	O
O	85	93	vascular	vascular	JJ	B-NP
O	94	105	endothelial	endothelial	JJ	I-NP
O	106	112	growth	growth	NN	I-NP
O	113	119	factor	factor	NN	I-NP
O	119	120	,	,	,	O
O	121	124	and	and	CC	O
O	125	136	interleukin	interleukin	NN	B-NP
O	136	137	-	-	HYPH	O
O	137	138	8	8	CD	B-NP
O	139	149	expression	expression	NN	I-NP
O	150	152	in	in	IN	B-PP
O	153	160	hypoxic	hypoxic	JJ	B-NP
O	161	166	human	human	JJ	I-NP
B-Cell	167	172	colon	colon	NN	I-NP
I-Cell	173	179	cancer	cancer	NN	I-NP
I-Cell	180	185	cells	cell	NNS	I-NP
O	185	186	.	.	.	O

O	187	195	Frequent	Frequent	JJ	B-NP
O	196	202	coffee	coffee	NN	I-NP
O	203	214	consumption	consumption	NN	I-NP
O	215	218	has	have	VBZ	B-VP
O	219	223	been	be	VBN	I-VP
O	224	234	associated	associate	VBN	I-VP
O	235	239	with	with	IN	B-PP
O	240	241	a	a	DT	B-NP
O	242	249	reduced	reduce	VBN	I-NP
O	250	254	risk	risk	NN	I-NP
O	255	257	of	of	IN	B-PP
B-Cancer	258	268	colorectal	colorectal	JJ	B-NP
I-Cancer	269	275	cancer	cancer	NN	I-NP
O	276	278	in	in	IN	B-PP
O	279	280	a	a	DT	B-NP
O	281	287	number	number	NN	I-NP
O	288	290	of	of	IN	B-PP
O	291	295	case	case	NN	O
O	295	296	-	-	HYPH	O
O	296	303	control	control	NN	B-NP
O	304	311	studies	study	NNS	I-NP
O	311	312	.	.	.	O

O	313	319	Coffee	Coffee	NN	B-NP
O	320	322	is	be	VBZ	B-VP
O	323	324	a	a	DT	B-NP
O	325	332	leading	lead	VBG	I-NP
O	333	339	source	source	NN	I-NP
O	340	342	of	of	IN	B-PP
O	343	358	methylxanthines	methylxanthine	NNS	B-NP
O	358	359	,	,	,	O
O	360	364	such	such	JJ	B-PP
O	365	367	as	as	IN	I-PP
O	368	376	caffeine	caffeine	NN	B-NP
O	376	377	.	.	.	O

O	378	381	The	The	DT	B-NP
O	382	391	induction	induction	NN	I-NP
O	392	394	of	of	IN	B-PP
O	395	403	vascular	vascular	JJ	B-NP
O	404	415	endothelial	endothelial	JJ	I-NP
O	416	422	growth	growth	NN	I-NP
O	423	429	factor	factor	NN	I-NP
O	430	431	(	(	(	O
O	431	435	VEGF	VEGF	NN	B-NP
O	435	436	)	)	)	O
O	437	440	and	and	CC	O
O	441	452	interleukin	interleukin	NN	B-NP
O	452	453	-	-	HYPH	O
O	453	454	8	8	CD	B-NP
O	455	456	(	(	(	O
O	456	458	IL	IL	NN	B-NP
O	458	459	-	-	HYPH	B-NP
O	459	460	8	8	CD	I-NP
O	460	461	)	)	)	O
O	462	464	is	be	VBZ	B-VP
O	465	467	an	an	DT	B-NP
O	468	477	essential	essential	JJ	I-NP
O	478	485	feature	feature	NN	I-NP
O	486	488	of	of	IN	B-PP
B-Cancer	489	494	tumor	tumor	NN	B-NP
O	495	507	angiogenesis	angiogenesis	NN	I-NP
O	507	508	,	,	,	O
O	509	512	and	and	CC	O
O	513	516	the	the	DT	B-NP
O	517	524	hypoxia	hypoxia	NN	I-NP
O	524	525	-	-	HYPH	O
O	525	534	inducible	inducible	JJ	B-NP
O	535	541	factor	factor	NN	I-NP
O	541	542	-	-	HYPH	B-NP
O	542	543	1	1	CD	I-NP
O	544	545	(	(	(	O
O	545	548	HIF	HIF	NN	O
O	548	549	-	-	HYPH	O
O	549	550	1	1	CD	O
O	550	551	)	)	)	O
O	552	565	transcription	transcription	NN	B-NP
O	566	572	factor	factor	NN	I-NP
O	573	575	is	be	VBZ	B-VP
O	576	581	known	know	VBN	I-VP
O	582	584	to	to	TO	I-VP
O	585	587	be	be	VB	I-VP
O	588	589	a	a	DT	B-NP
O	590	593	key	key	JJ	I-NP
O	594	603	regulator	regulator	NN	I-NP
O	604	606	of	of	IN	B-PP
O	607	611	this	this	DT	B-NP
O	612	619	process	process	NN	I-NP
O	619	620	.	.	.	O

O	621	623	In	In	IN	B-PP
O	624	628	this	this	DT	B-NP
O	629	634	study	study	NN	I-NP
O	634	635	,	,	,	O
O	636	638	we	we	PRP	B-NP
O	639	651	investigated	investigate	VBD	B-VP
O	652	655	the	the	DT	B-NP
O	656	663	effects	effect	NNS	I-NP
O	664	666	of	of	IN	B-PP
O	667	675	caffeine	caffeine	NN	B-NP
O	676	678	on	on	IN	B-PP
O	679	682	HIF	HIF	NN	B-NP
O	682	683	-	-	HYPH	B-NP
O	683	684	1	1	CD	I-NP
O	685	692	protein	protein	NN	I-NP
O	693	705	accumulation	accumulation	NN	I-NP
O	706	709	and	and	CC	B-PP
O	710	712	on	on	IN	B-PP
O	713	717	VEGF	VEGF	NN	B-NP
O	718	721	and	and	CC	I-NP
O	722	724	IL	IL	NN	I-NP
O	724	725	-	-	HYPH	O
O	725	726	8	8	CD	B-NP
O	727	737	expression	expression	NN	I-NP
O	738	740	in	in	IN	B-PP
O	741	744	the	the	DT	B-NP
O	745	750	human	human	JJ	I-NP
B-Cell	751	756	colon	colon	NN	I-NP
I-Cell	757	763	cancer	cancer	NN	I-NP
I-Cell	764	768	cell	cell	NN	I-NP
I-Cell	769	773	line	line	NN	I-NP
I-Cell	774	778	HT29	HT29	NN	I-NP
O	779	784	under	under	IN	B-PP
O	785	792	hypoxic	hypoxic	JJ	B-NP
O	793	803	conditions	condition	NNS	I-NP
O	803	804	.	.	.	O

O	805	808	Our	Our	PRP$	B-NP
O	809	816	results	result	NNS	I-NP
O	817	821	show	show	VBP	B-VP
O	822	826	that	that	IN	B-SBAR
O	827	835	caffeine	caffeine	NN	B-NP
O	836	849	significantly	significantly	RB	B-ADVP
O	850	858	inhibits	inhibit	VBZ	B-VP
O	859	868	adenosine	adenosine	NN	B-NP
O	868	869	-	-	HYPH	O
O	869	876	induced	induce	VBN	B-NP
O	877	880	HIF	HIF	NN	I-NP
O	880	881	-	-	HYPH	B-NP
O	881	887	1alpha	1alpha	NN	I-NP
O	888	895	protein	protein	NN	I-NP
O	896	908	accumulation	accumulation	NN	I-NP
O	909	911	in	in	IN	B-PP
B-Cell	912	918	cancer	cancer	NN	B-NP
I-Cell	919	924	cells	cell	NNS	I-NP
O	924	925	.	.	.	O

O	926	928	We	We	PRP	B-NP
O	929	933	show	show	VBP	B-VP
O	934	938	that	that	IN	B-SBAR
O	939	942	HIF	HIF	NN	B-NP
O	942	943	-	-	HYPH	B-NP
O	943	949	1alpha	1alpha	NN	I-NP
O	950	953	and	and	CC	I-NP
O	954	958	VEGF	VEGF	NN	I-NP
O	959	962	are	be	VBP	B-VP
O	963	972	increased	increase	VBN	I-VP
O	973	980	through	through	IN	B-PP
O	981	983	A3	A3	NN	B-NP
O	984	993	adenosine	adenosine	NN	I-NP
O	994	1002	receptor	receptor	NN	I-NP
O	1003	1014	stimulation	stimulation	NN	I-NP
O	1014	1015	,	,	,	O
O	1016	1023	whereas	whereas	IN	O
O	1024	1027	the	the	DT	B-NP
O	1028	1035	effects	effect	NNS	I-NP
O	1036	1038	on	on	IN	B-PP
O	1039	1041	IL	IL	NN	B-NP
O	1041	1042	-	-	HYPH	O
O	1042	1043	8	8	CD	B-NP
O	1044	1047	are	be	VBP	B-VP
O	1048	1056	mediated	mediate	VBN	I-VP
O	1057	1060	via	via	IN	B-PP
O	1061	1064	the	the	DT	B-NP
O	1065	1068	A2B	A2B	NN	I-NP
O	1069	1076	subtype	subtype	NN	I-NP
O	1076	1077	.	.	.	O

O	1078	1090	Pretreatment	Pretreatment	NN	B-NP
O	1091	1093	of	of	IN	B-PP
B-Cell	1094	1099	cells	cell	NNS	B-NP
O	1100	1104	with	with	IN	B-PP
O	1105	1113	caffeine	caffeine	NN	B-NP
O	1114	1127	significantly	significantly	RB	B-ADVP
O	1128	1135	reduces	reduce	VBZ	B-VP
O	1136	1145	adenosine	adenosine	NN	B-NP
O	1145	1146	-	-	HYPH	B-NP
O	1146	1153	induced	induce	VBN	I-NP
O	1154	1158	VEGF	VEGF	NN	I-NP
O	1159	1167	promoter	promoter	NN	I-NP
O	1168	1176	activity	activity	NN	I-NP
O	1177	1180	and	and	CC	O
O	1181	1185	VEGF	VEGF	NN	B-NP
O	1186	1189	and	and	CC	I-NP
O	1190	1192	IL	IL	NN	I-NP
O	1192	1193	-	-	HYPH	O
O	1193	1194	8	8	CD	B-NP
O	1195	1205	expression	expression	NN	I-NP
O	1205	1206	.	.	.	O

O	1207	1210	The	The	DT	B-NP
O	1211	1220	mechanism	mechanism	NN	I-NP
O	1221	1223	of	of	IN	B-PP
O	1224	1232	caffeine	caffeine	NN	B-NP
O	1233	1238	seems	seem	VBZ	B-VP
O	1239	1241	to	to	TO	I-VP
O	1242	1249	involve	involve	VB	I-VP
O	1250	1253	the	the	DT	B-NP
O	1254	1264	inhibition	inhibition	NN	I-NP
O	1265	1267	of	of	IN	B-PP
O	1268	1271	the	the	DT	B-NP
O	1272	1285	extracellular	extracellular	JJ	I-NP
O	1286	1292	signal	signal	NN	I-NP
O	1292	1293	-	-	HYPH	O
O	1293	1302	regulated	regulate	VBN	B-VP
O	1303	1309	kinase	kinase	NN	B-NP
O	1310	1311	1	1	CD	I-NP
O	1311	1312	/	/	SYM	B-NP
O	1312	1313	2	2	CD	I-NP
O	1314	1315	(	(	(	O
O	1315	1319	ERK1	ERK1	NN	B-NP
O	1319	1320	/	/	SYM	O
O	1320	1321	2	2	CD	B-NP
O	1321	1322	)	)	)	O
O	1322	1323	,	,	,	O
O	1324	1327	p38	p38	NN	B-NP
O	1327	1328	,	,	,	O
O	1329	1332	and	and	CC	O
O	1333	1336	Akt	Akt	NN	B-NP
O	1336	1337	,	,	,	O
O	1338	1345	leading	lead	VBG	B-VP
O	1346	1348	to	to	TO	B-PP
O	1349	1350	a	a	DT	B-NP
O	1351	1357	marked	marked	JJ	I-NP
O	1358	1366	decrease	decrease	NN	I-NP
O	1367	1369	in	in	IN	B-PP
O	1370	1379	adenosine	adenosine	NN	B-NP
O	1379	1380	-	-	HYPH	O
O	1380	1387	induced	induce	VBN	B-NP
O	1388	1391	HIF	HIF	NN	I-NP
O	1391	1392	-	-	HYPH	B-NP
O	1392	1398	1alpha	1alpha	NN	I-NP
O	1399	1411	accumulation	accumulation	NN	I-NP
O	1411	1412	,	,	,	O
O	1413	1417	VEGF	VEGF	NN	B-NP
O	1418	1433	transcriptional	transcriptional	JJ	I-NP
O	1434	1444	activation	activation	NN	I-NP
O	1444	1445	,	,	,	O
O	1446	1449	and	and	CC	O
O	1450	1454	VEGF	VEGF	NN	B-NP
O	1455	1458	and	and	CC	I-NP
O	1459	1461	IL	IL	NN	I-NP
O	1461	1462	-	-	HYPH	O
O	1462	1463	8	8	CD	B-NP
O	1464	1471	protein	protein	NN	I-NP
O	1472	1484	accumulation	accumulation	NN	I-NP
O	1484	1485	.	.	.	O

O	1486	1490	From	From	IN	B-PP
O	1491	1492	a	a	DT	B-NP
O	1493	1503	functional	functional	JJ	I-NP
O	1504	1515	perspective	perspective	NN	I-NP
O	1515	1516	,	,	,	O
O	1517	1519	we	we	PRP	B-NP
O	1520	1527	observe	observe	VBP	B-VP
O	1528	1532	that	that	IN	B-SBAR
O	1533	1541	caffeine	caffeine	NN	B-NP
O	1542	1546	also	also	RB	B-ADVP
O	1547	1560	significantly	significantly	RB	B-ADVP
O	1561	1569	inhibits	inhibit	VBZ	B-VP
O	1570	1573	the	the	DT	B-NP
O	1574	1576	A3	A3	NN	I-NP
O	1577	1585	receptor	receptor	NN	I-NP
O	1585	1586	-	-	HYPH	B-VP
O	1586	1596	stimulated	stimulate	VBN	B-NP
B-Cell	1597	1601	cell	cell	NN	I-NP
O	1602	1611	migration	migration	NN	I-NP
O	1612	1614	of	of	IN	B-PP
B-Cell	1615	1620	colon	colon	NN	B-NP
I-Cell	1621	1627	cancer	cancer	NN	I-NP
I-Cell	1628	1633	cells	cell	NNS	I-NP
O	1633	1634	.	.	.	O

O	1635	1646	Conditioned	Condition	VBN	B-NP
O	1647	1652	media	medium	NNS	I-NP
O	1653	1661	prepared	prepare	VBN	B-VP
O	1662	1666	from	from	IN	B-PP
B-Cell	1667	1672	colon	colon	NN	B-NP
I-Cell	1673	1678	cells	cell	NNS	I-NP
O	1679	1686	treated	treat	VBN	B-VP
O	1687	1691	with	with	IN	B-PP
O	1692	1694	an	an	DT	B-NP
O	1695	1704	adenosine	adenosine	NN	I-NP
O	1705	1711	analog	analog	NN	I-NP
O	1712	1721	increased	increase	VBD	B-VP
B-Cell	1722	1727	human	human	JJ	B-NP
I-Cell	1728	1737	umbilical	umbilical	JJ	I-NP
I-Cell	1738	1742	vein	vein	NN	I-NP
I-Cell	1743	1754	endothelial	endothelial	JJ	I-NP
I-Cell	1755	1759	cell	cell	NN	I-NP
O	1760	1769	migration	migration	NN	I-NP
O	1769	1770	.	.	.	O

O	1771	1776	These	These	DT	B-NP
O	1777	1781	data	datum	NNS	I-NP
O	1782	1789	provide	provide	VBP	B-VP
O	1790	1798	evidence	evidence	NN	B-NP
O	1799	1803	that	that	IN	B-SBAR
O	1804	1813	adenosine	adenosine	NN	B-NP
O	1814	1819	could	could	MD	B-VP
O	1820	1828	modulate	modulate	VB	I-VP
O	1829	1832	the	the	DT	B-NP
O	1833	1842	migration	migration	NN	I-NP
O	1843	1845	of	of	IN	B-PP
B-Cell	1846	1851	colon	colon	NN	B-NP
I-Cell	1852	1858	cancer	cancer	NN	I-NP
I-Cell	1859	1864	cells	cell	NNS	I-NP
O	1865	1867	by	by	IN	B-PP
O	1868	1870	an	an	DT	B-NP
O	1871	1874	HIF	HIF	NN	I-NP
O	1874	1875	-	-	HYPH	I-NP
O	1875	1881	1alpha	1alpha	NN	I-NP
O	1881	1882	/	/	SYM	I-NP
O	1882	1886	VEGF	VEGF	NN	I-NP
O	1886	1887	/	/	SYM	B-NP
O	1887	1889	IL	IL	NN	I-NP
O	1889	1890	-	-	HYPH	B-NP
O	1890	1891	8	8	CD	I-NP
O	1891	1892	-	-	HYPH	I-NP
O	1892	1901	dependent	dependent	JJ	I-NP
O	1902	1911	mechanism	mechanism	NN	I-NP
O	1912	1915	and	and	CC	O
O	1916	1920	that	that	IN	B-SBAR
O	1921	1929	caffeine	caffeine	NN	B-NP
O	1930	1933	has	have	VBZ	B-VP
O	1934	1937	the	the	DT	B-NP
O	1938	1947	potential	potential	NN	I-NP
O	1948	1950	to	to	TO	B-VP
O	1951	1958	inhibit	inhibit	VB	I-VP
B-Cell	1959	1964	colon	colon	NN	B-NP
I-Cell	1965	1971	cancer	cancer	NN	I-NP
I-Cell	1972	1976	cell	cell	NN	I-NP
O	1977	1983	growth	growth	NN	I-NP
O	1983	1984	.	.	.	O

